Claude Cochet
Overview
Explore the profile of Claude Cochet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalifa H, ElHady A, Liu T, Elgaher W, Filhol-Cochet O, Cochet C, et al.
Eur J Med Chem
. 2024 Nov;
282:117048.
PMID: 39566243
CK2 is a Ser/Thr-protein kinase playing a crucial role in promoting cell growth and survival, hence it is considered a promising target for anti-cancer drugs. However, many previously reported CK2...
2.
Cesana B, Cochet C, Filhol O
Int J Cancer
. 2024 Sep;
156(3):475-487.
PMID: 39306698
Approximately one-third of advanced renal cell carcinoma (RCC) patients develop osteolytic bone metastases, leading to skeletal complications. In this review, we first provide a comprehensive perspective of seminal studies on...
3.
Author Correction: GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway
Park A, Leney-Greene M, Lynberg M, Gabrielski J, Xu X, Schwarz B, et al.
Nat Immunol
. 2024 Feb;
25(4):717.
PMID: 38347083
No abstract available.
4.
Bancet A, Frem R, Jeanneret F, Mularoni A, Bazelle P, Roelants C, et al.
iScience
. 2024 Feb;
27(2):108903.
PMID: 38318383
Although the involvement of protein kinase CK2 in cancer is well-documented, there is a need for selective CK2 inhibitors suitable for investigating CK2 specific roles in cancer-related biological pathways and...
5.
Park A, Leney-Greene M, Lynberg M, Gabrielski J, Xu X, Schwarz B, et al.
Nat Immunol
. 2024 Jan;
25(2):282-293.
PMID: 38172257
Preserving cells in a functional, non-senescent state is a major goal for extending human healthspans. Model organisms reveal that longevity and senescence are genetically controlled, but how genes control longevity...
6.
Seraudie I, Pillet C, Cesana B, Bazelle P, Jeanneret F, Evrard B, et al.
Cell Death Dis
. 2023 Sep;
14(9):622.
PMID: 37736770
Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous...
7.
Koca D, Seraudie I, Jardillier R, Cochet C, Filhol O, Guyon L
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345040
Clear-cell renal cell carcinoma (ccRCC) accounts for 75% of kidney cancers. Due to the high recurrence rate and treatment options that come with high costs and potential side effects, a...
8.
Coste K, Bruet S, Chollat-Namy C, Filhol O, Cochet C, Gallot D, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835482
At the feto-maternal interface, fetal membranes (FM) play a crucial role throughout pregnancy. FM rupture at term implicates different sterile inflammation mechanisms including pathways activated by the transmembrane glycoprotein receptor...
9.
Filhol O, Hesse A, Bouin A, Albiges-Rizo C, Jeanneret F, Battail C, et al.
Front Mol Biosci
. 2022 Jul;
9:900947.
PMID: 35847979
CK2 is a hetero-tetrameric serine/threonine protein kinase made up of two CK2α/α' catalytic subunits and two CK2β regulatory subunits. The free CK2α subunit and the tetrameric holoenzyme have distinct substrate...
10.
Giacosa S, Pillet C, Seraudie I, Guyon L, Wallez Y, Roelants C, et al.
Cancers (Basel)
. 2021 Feb;
13(3).
PMID: 33540838
Kinase-targeted agents demonstrate antitumor activity in advanced metastatic clear cell renal cell carcinoma (ccRCC), which remains largely incurable. Integration of genomic approaches through small-molecules and genetically based high-throughput screening holds...